Poon Ronnie Tung-Ping, Fan Sheung Tat, Wong John
Centre for the Study of Liver Disease and the Department of Surgery, University of Hong Kong Medical Centre, Queen Mary Hospital, China.
J Am Coll Surg. 2002 May;194(5):592-602. doi: 10.1016/s1072-7515(02)01163-8.
The role of hepatic resection for large hepatocellular carcinoma (HCC) larger than 10 cm remains unclear.
Perioperative and longterm outcomes of 120 patients with HCC larger than 10 cm who underwent resection (group A) were compared with 368 patients with smaller HCC (group B). The prognostic factors in group A were analyzed.
A higher proportion of patients underwent major hepatic resection in group A than in group B (90% versus 57.6%, p = 0.001), but the hospital mortality was similar (5.0% versus 4.6%, p = 0.874). Group A had worse longterm overall survival (median 18.8 months versus 62.8 months, p < 0.001) and disease-free survival (median 5.5 months versus 25.4 months, p < 0.001) than group B. Macroscopic residual tumor, macroscopic venous invasion, and multiple tumors were identified as independent prognostic factors in group A. The median survival of patients with residual tumor and those with curative resection was 7.7 months and 20.8 months, respectively. The median survival of patients with curative resection of solitary HCC larger than 10cm without macroscopic venous invasion was 38.0 months; that of patients with both macroscopic venous invasion and multiple tumors was only 10.5 months.
Hepatic resection is a safe and effective treatment for HCC larger than 10cm when liver function reserve is satisfactory and when curative resection can be expected. Patients with solitary HCC larger than 10cm without macroscopic venous invasion can enjoy longterm survival after surgery, and we propose hepatic resection as a standard treatment for this group of patients.
肝切除治疗直径大于10cm的大肝细胞癌(HCC)的作用仍不明确。
将120例接受肝切除的直径大于10cm的HCC患者(A组)的围手术期和长期结局与368例较小HCC患者(B组)进行比较。分析A组的预后因素。
A组接受大范围肝切除的患者比例高于B组(90%对57.6%,p = 0.001),但医院死亡率相似(5.0%对4.6%,p = 0.874)。A组的长期总生存期(中位数18.8个月对62.8个月,p < 0.001)和无病生存期(中位数5.5个月对25.4个月,p < 0.001)均比B组差。肉眼可见的残留肿瘤、肉眼可见的静脉侵犯和多发肿瘤被确定为A组的独立预后因素。有残留肿瘤的患者和接受根治性切除的患者的中位生存期分别为7.7个月和20.8个月。对直径大于10cm、无肉眼可见静脉侵犯的孤立性HCC进行根治性切除的患者的中位生存期为38.0个月;既有肉眼可见静脉侵犯又有多发肿瘤的患者的中位生存期仅为10.5个月。
当肝功能储备良好且有望进行根治性切除时,肝切除是治疗直径大于1cm的HCC的一种安全有效的方法。直径大于10cm、无肉眼可见静脉侵犯的孤立性HCC患者术后可获得长期生存,我们建议将肝切除作为这组患者的标准治疗方法。